Physician panel to discuss issues related to Qutenza at Investor Day

Apr 24 2010

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and CEO, and members of the NeurogesX management team, will host an Investor Day on Friday, April 30, 2010, from 8:15am-11:00am EDT in New York City.

The Investor Day will be webcast live and archived for 30 days on the investor relations section of the NeurogesX website at www.neurogesx.com.

Following the recent U.S. launch of Qutenza® (capsaicin) 8% patch, NeurogesX's senior management will review the commercialization strategy and provide an update on reimbursement. Upcoming research and development activities will also be discussed.

In addition, a physician panel will discuss issues related to the practice of pain medicine, experiences and patient reactions to Qutenza and will also discuss its integration into physician practice for the treatment of postherpetic neuralgia (PHN):

• Dr. Richard Rauck, M.D., a board-certified anesthesiologist, CEO and Medical Director of the Carolinas Pain Institute and Clinical Associate Professor at Wake Forest University Health Sciences
• Dr. David Simpson, M.D., a Professor of Neurology at Mount Sinai School of Medicine, Director of the Clinical Neurophysiology Laboratories and Director of the Neuro-AIDS Program at Mount Sinai Hospital
• Dr. Lynn Webster, M.D., F.A.C.P.M., F.A.S.A.M., cofounder and medical director of Lifetree Clinical Research who is board certified in anesthesiology and pain management